Log In
BCIQ
Print this Print this
 

VY-AADC01

  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionAdeno-associated virus (AAV) serotype 2 capsid and a cytomegalovirus promoter designed to deliver the dopa decarboxylase (DDC; AADC) gene directly into the putamen
Molecular Target Dopa decarboxylase (DDC) (AADC)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat advanced Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$845.0M

$70.0M

$745.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/11/2015

$845.0M

$70.0M

$745.0M

Get a free BioCentury trial today